Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Sorafenib in Metastatic Differentiated Thyroid Cancer
NCT01263951Phase 2Unknown
- Sponsor
- Thomas Jefferson University
- Start
- Nov 2010
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in differentiated thyroid cancer (DTC), sponsored by Thomas Jefferson University. Primary endpoints: Progression Free Survival, Objective Response Rate and 1 more. Status: unknown.
02
Drugs
everolimus
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT01263951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263951.